Budget impact analysis in Spanish patients with Dupuytren's contracture: Fasciectomy vs. collagenase Clostridium histolyticum

Chirurgie de la Main

Volumn 32, Issue 2, 2013, Pages 68-73

  De Salas Cansado, M ^a   Cuadros, M ^b   Del Cerro, M ^c   Arandes, J M ^d  

^a PFIZER INC   (United States)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c Hospital Beata Maria Ana   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

Budget impact analysis; Collagenase clostridium histolyticum; Cost minimization; Dupuytren contracture; Fasciectomy

Indexed keywords

CLOSTRIDIOPEPTIDASE A;

ARTICLE; CLINICAL EFFECTIVENESS; COST MINIMIZATION ANALYSIS; DRUG COST; DUPUYTREN CONTRACTURE; FASCIECTOMY; HEALTH CARE COST; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; OPERATING ROOM; OUTPATIENT; SENSITIVITY ANALYSIS; SPAIN; SURGICAL TECHNIQUE;

AMBULATORY CARE; CLOSTRIDIUM HISTOLYTICUM; COSTS AND COST ANALYSIS; DUPUYTREN CONTRACTURE; FASCIA; HOSPITALIZATION; HUMANS; INJECTIONS, INTRALESIONAL; MICROBIAL COLLAGENASE; ORTHOPEDIC PROCEDURES; RETROSPECTIVE STUDIES; SPAIN;

EID: 84876983479     PISSN: 12973203     EISSN: 17696666     Source Type: Journal    
DOI: 10.1016/j.main.2013.02.012     Document Type: Article

References (40)

1. Khashan M., Smitham P.J., Khan W.S., Goddard N.J. Dupuytren's disease: review of the current literature. Open Orthop J 2011, 5:283-288.
2. Hurst L.C., Badalamente M.A., Hentz V.R., Hotchkiss R.N., Kaplan F.T., Meals R.A., et al. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med 2009, 361:968-979.
3. Witthaut J., Bushmakin A., Gerber R.A., Cappelleri J.C., Hellio Le Graverand-Gastineau M.P. Determining clinically important changes in range of motion in patients with Dupuytren's contracture. Clin Drug Investig 2011, 31:791-798.
4. Brenner P., Mailänder P., Berger A. Epidemiology of Dupuytren's disease. Dupuytren's disease 1994, 244-254. Sprinter-Verlag, Berlin. A. Berger, A. Delbrüsk, P. Brenner, R. Hinzmann (Eds.).
5. Ross D. Epidemiology of Dupuytren's disease. Hand Clin 1999, 15:53-62.
6. Wylock P. In the footsteps of Guillaume Dupuytren. Acta Chir Belg 1997, 97:277-280.
7. Sáez Aldana F., Gonzalez del Pino J., Delgado A., Lovic A. Epidemiologia de la enfermedad de Dupuytren. Analisis de 314 casos. Rev Ortop Traumatol 1996, 40:15-21.
8. Quintana Guitian A. Quelques aspects épidémiologiques de la maladie de Dupuytren. Ann Chir Main 1988, 7:256-262.
9. Burge P., Hoy G., Regan P., Milne R. Smoking alcohol and the risk of Dupuytren's contracture. J Bone Joint Surg Br 1997, 79:206-210.
10. Noble J., Arafa M., Royle S.G., McGeorge G., Crank S. The association between alcohol, hepatic pathology and Dupuytren's disease. J Hand Surg Br 1992, 17:71-74.
11. Renard E., Jacques D., Chammas M., Poirier J.L., Bonifacj C., Jaffiol C., et al. Increased prevalence of soft tissue hand lesions in type 1 and type 2 diabetes mellitus: various entities and associated significance. Diabete Metab 1994, 20:513-521.
12. Critchley E.M., Vakil S.D., Hayward H.W., Owen V.M. Dupuytren's disease in epilepsy: result of prolonged administration of anticonvulsants. J Neurol Neurosurg Psychiatry 1976, 39:498-503.
13. Bower M., Nelson M., Gazzard B.G. Dupuytren's contractures in patients infected with HIV. BMJ 1990, 300:164-165.
14. Coert J.H., Nérin J.P., Meek M.F. Results of partial fasciectomy for Dupuytren disease in 261 consecutive patients. Ann Plast Surg 2006, 57:13-17.
15. Gilpin D., Coleman S., Hall S., Houston A., Karrasch J., Jones N. Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease. Hand Surg 2010, 35:2027-2038.
16. Pérez Mandanero M.A., Pavón de Paz M., Roldan Laguarta P. Tratamiento rehabilitador de la enfermedad de Dupuytren. Rehabilitation 2003, 37:272-277.
17. Calderón González A.M., López Moya A., Rodríguez Cerdeira C., Braña Tobio J.C. Actualización de la enfermedad de Dupuytren. Rehabilitation 2003, 37:264-271.
18. Crean S.M., Gerber R.A., Hellio Le Graverand M.P., Boyd D.M., Cappelleri J.C. The efficacy and safety of fasciectomy and fasciotomy for Dupuytren's contracture in European patients: a structured review of published studies. J Hand Surg Eur 2011, 36:396-407.
19. Herrera Rodríguez A., Pérez García J.M. Enfermedad de Dupuytren. Monografías medico-quirúrgicas del aparato locomotor 1999, Masson, Barcelona, p. 39-59. 5.
20. Maravic M., Landais P. Dupuytren's disease in France -1831 to 2001- from description to economic burden. J Hand Surg Br 2005, 30:484-487.
21. Gerber R.A., Perry R., Thompson R., Bainbridge C. Dupuytren's contracture: a retrospective database analysis to assess clinical management and costs in England. BMC Muscul Disord 2011, 12:73.
22. Loos B., Puschkin V., Horch R.E. 50years experience with Dupuytren's contracture in the Erlangen University Hospital- a retrospective analysis of 2919 operated hands from 1956 to 2006. BMC Musculoskelet Disord 2007, 8:60.
23. Calderón González A.M., López Moya A., Rodríguez Cerdeira C., Braña Tobio J.C. La enfermedad de Dupuytren en Galicia. Cir Plast Iberlatinamer 2004, 30:325-332.
24. http://www.msps.es/estadEstudios/estadisticas/sisInfSanSNS/aplicacionesConsulta/home.htm (CMBD-H y CMBD AAE).(consulted April 2010).
25. Ines M, Silverino N, Erdogan-Ciftci E. Cost minimization analysis of collagenase clostridium histolyticum compared with fasciectomy in patients with Dupuytren's contracture in Portugal. 2011 ISPOR congress.
26. Xiapex Summary of Product Characteristics.
27. Badalamente M.A., Hurst L.C. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren's contracture. J Hand Surg Am 2007, 32:767-774.
28. Starkweather K.D., Lattuga S., Hurst L.C., Badalamente M.A., Guilak F., Samson S.P., et al. Collagenase in the treatment of Dupuytren's disease: an in vitro study. J Hand Surg Am 1996, 21:490-495.
29. Banegas J.R., Jovel A., Abarca B., Aguilar M., Aguilera L., Aranda P., et al. Hipertensión arterial y política de salud en España. Med Clin (Barc) 2009, 132:222-229.
30. Marshall D.A., Douglas P.R., Drummond M.F., Torrance G.W., Macleod S., Manti O., et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Pharmacoeconomics 2008, 26:477-495.
31. Chen N.C., Shauver M.J., Chung K.C. Cost-effectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for Dupuytren contracture. J Hand Surg Am 2011, 36:1826-1834.
32. USA Real life Skodny P., Mackowiak J.I. Efficacy and effectiveness of collagenase clostridium histolyticum for Dupuytren's contracture 2011, ISPOR 14th Annual European Congress, Madrid, Spain, [5-8 November, Value in Health 14 (2011) A 302; PMS4].
33. Base de datos E Salud - Información económica del sector sanitario http://www.oblikue.com/bddcostes/.(consulted April 2011).
34. Catálogo del Consejo General de Colegios Farmacéuticos de España 2011.
35. Real Decreto-Ley 8/2010, May 20th where extraordinary measures were adopted for public deficit reduction.
36. Denkler K. Surgical complications associated with fasciectomy for Dupuytren's disease: a 20year review of the English literature. Eplasty 2010, 10:116-133.
37. Amillo Garayoa S., Losada Viñas J.I., Leyes Vence M., Schweitzer Fernández D. Evolución a largo plazo de las manos operadas por enfermedad de Dupuytren. Rev Ortop Traum 1994, 38:275-281.
38. Tubiana R., Michon J., Thomine J.M. Scheme for the assessment of deformities in Dupuytren's disease. Surg Clin North Am 1968, 48:979-984.
39. McFarlane R., McDermid J. Dupuytren's disease. Rehabilitation of the hand. Surgery and therapy 1995, 981-984. Mosby, St Louis, MO. 4. J. Hunter, L. Schneider, E. Mackin, A. Callahan (Eds.).
40. Bainbridge C., Gerber R.A., Szczypa P.P., Smith T., Kushner H., Cohen B., et al. Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren's contracture. J Plastic Surg Hand Surg 2012, 46:177-183.